Quantum dot and plasma nanoparticle coupling method and strong coupling device

Abstract

The invention discloses a method for coupling quantum dots and plasma nanoparticles and a strong coupling device, and the method is characterized in that the quantum dots and the plasma nanoparticles are connected through amido bonds to construct a composite system capable of realizing strong coupling. The quantum dots and the plasma nanoparticles are connected through amido bonds, the problem that in an existing quantum dot and plasma nanoparticle coupling method, reaction conditions are harsh is solved, the formed product structure is extremely stable, the reliability of a system is effectively improved, waste is reduced, and the environment-friendly requirement is met.

Description

Technical Field

[0001] The present invention relates to the field of plasmon technology, and in particular to a method for coupling quantum dots and plasma nanoparticles and a strong coupling device. Background Art

[0002] Light-matter interaction is a fundamental phenomenon in nature. In its most basic form, it can be understood as the interaction between a single quantum emitter and a single photon. Depending on the strength of the interaction, light-matter interactions are primarily categorized as weak coupling and strong coupling. Weak coupling is a key concept in physics, describing the situation where the interaction between two or more systems is relatively weak. In this case, the properties and behavior of the systems are primarily determined by their internal dynamics, with the influence of the interaction being relatively small. Unlike weak coupling, strong coupling can foster the formation of hybrid polaritonic quasiparticles, demonstrating coherent energy exchange between the coupled subsystems on extremely fast timescales, far exceeding their dissipative dynamics. This strong light-matter interaction (strong coupling) has attracted considerable attention, particularly when it reaches the quantum optical limit, enabling the creation and manipulation of quantum states at the single-photon level. This has opened up unprecedented opportunities for the development of numerous quantum technologies, such as quantum optical circuits, ultra-low-power lasers, quantum computing, and quantum networks.

[0003] Integrating nanoemitters into plasmonic devices with spatial control and nanometer precision has always been a challenging problem. Current conventional methods are often accompanied by complex process flows, high production costs, and low yields, making large-scale industrial production difficult. In addition, existing methods for coupling quantum dots with plasmonic nanoparticles have many problems, such as overly harsh reaction conditions, insufficient stability of synthetic samples, complex and tedious operation procedures, and the generation of large amounts of waste. These factors have seriously restricted their widespread promotion in practical applications.

[0004] Therefore, the existing technology still needs to be improved and developed. Summary of the Invention

[0005] In view of the above-mentioned deficiencies in the prior art, the present invention provides a method for coupling quantum dots and plasma nanoparticles and a strong coupling device to solve the problem of insufficient stability of the synthesized products using the existing quantum dot and plasma nanoparticle coupling methods.

[0006] The technical solutions adopted by the present invention to solve the above technical problems are as follows:

[0007] A first aspect of the present invention provides a method for coupling quantum dots and plasma nanoparticles, characterized in that the method connects quantum dots and plasma nanoparticles through amide bonds to construct a composite system that can achieve strong coupling.

[0008] Preferably, the method connects the quantum dots to the plasmonic nanoparticles via an amide bond, and the specific method steps are:

[0009] Method 1:

[0010] mixing the plasma nanoparticle solution with a solution containing an amino-functionalized compound to react and obtain amino-functionalized plasma nanoparticles;

[0011] Providing a quantum dot solution, wherein the quantum dots have carboxyl groups connected to their surfaces, mixing the quantum dot solution with a cross-linking agent, and activating the carboxyl groups to obtain an activated quantum dot solution;

[0012] mixing the amino-functionalized plasma nanoparticles with the activated quantum dot solution to generate an amide reaction, so that the quantum dots and the plasma nanoparticles are connected by an amide bond, thereby completing the coupling of the quantum dots and the plasma nanoparticles;

[0013] Method 2:

[0014] mixing the plasma nanoparticle solution with a solution containing a carboxyl functionalized compound to perform carboxyl functionalization, so that the surface of the plasma nanoparticles is modified with carboxyl groups, thereby obtaining carboxyl functionalized plasma nanoparticles;

[0015] mixing the carboxyl functionalized plasma nanoparticles with a crosslinking agent to activate the carboxyl groups to obtain activated plasma nanoparticles;

[0016] Providing a quantum dot solution, wherein the quantum dots have amino groups attached to their surfaces;

[0017] The activated plasma nanoparticles are mixed with the quantum dot solution to generate an amide reaction, so that the quantum dots and the plasma nanoparticles are connected by an amide bond, thereby completing the coupling of the quantum dots and the plasma nanoparticles.

[0018] Preferably, the amino-functionalized compound is selected from amino-polyethylene glycol-thiol, and the carboxyl-functionalized compound is selected from carboxyl-polyethylene glycol-thiol.

[0019] Preferably, the surface of the plasma nanoparticles is modified by hexadecyltrimethylammonium bromide.

[0020] Preferably, in the method 1, the concentration of the plasma nanoparticle solution is 0.005-0.02 mg / mL, and the concentration of the solution containing the amino-functionalized compound is 2-8x10 -4 mol / L, the dosage ratio of the plasma nanoparticle solution to the solution containing the amino-functionalized compound is 1:(5-50); in the second method, the concentration of the plasma nanoparticle solution is 0.005-0.02 mg / mL, and the concentration of the solution containing the carboxyl-functionalized compound is 2-8x10 -4 mol / L, and the dosage ratio of the plasma nanoparticle solution to the solution containing the carboxyl functionalized compound is 1:(5-50).

[0021] Preferably, in the method one, before the step of mixing the amino-functionalized plasma nanoparticles with the activated quantum dot solution, the method further comprises the steps of: allowing the mixed solution obtained by reacting the plasma nanoparticle solution with the solution containing the amino-functionalized compound to stand and centrifuge in sequence, and then adding the obtained precipitate to N,N-dimethylformamide to obtain amino-functionalized plasma nanoparticles; in the method two, after the step of mixing the plasma nanoparticle solution with the solution containing the carboxyl-functionalized compound and performing carboxyl functionalization, the method further comprises the steps of: allowing the carboxyl-functionalized plasma nanoparticle solution to stand and centrifuge in sequence, and then adding the obtained precipitate to N,N-dimethylformamide to obtain carboxyl-functionalized plasma nanoparticles.

[0022] Preferably, in the method 1, the cross-linking agent includes 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysulfosuccinimide sodium salt.

[0023] Preferably, in the method 1, the step of mixing the quantum dot solution with the crosslinker is specifically: first adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to the quantum dot solution, and then adding N-hydroxysulfosuccinimide sodium salt.

[0024] Preferably, in the second method, the carboxyl-functionalized plasma nanoparticles are subjected to a carboxyl activation treatment, specifically comprising the following steps: first adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to the carboxyl-functionalized plasma nanoparticles, and then adding N-hydroxysulfosuccinimide sodium salt.

[0025] A second aspect of the present invention provides a quantum dot and plasma nanoparticle strong coupling device, wherein the quantum dot and plasma nanoparticle strong coupling device is obtained by coupling using the above method.

[0026] Beneficial effects:

[0027] The present invention discloses a method for coupling quantum dots and plasma nanoparticles and a strong coupling device. First, an amide bond is used to connect quantum dots and plasma nanoparticles, which solves the problems of harsh reaction conditions, complex operation, and many wastes in existing quantum dot and plasma nanoparticle coupling methods. The formed product structure is extremely stable, effectively improves the reliability of the system, simplifies the operation process, reduces the generation of waste, and meets environmental protection requirements. Secondly, in the present invention, quantum dots and plasma nanoparticles are connected by amide bonds, which solves the problems of complex process flow and high production costs in traditional methods, realizes large-scale preparation, greatly improves production efficiency, reduces production costs, and makes industrial production possible. Finally, the present invention solves the problem of insufficient coupling strength and difficulty in achieving efficient energy exchange in the prior art through a cleverly designed structure. It can further reduce the mode volume and more effectively localize the electric field, thereby significantly enhancing the coupling strength, making the energy exchange between quantum dots and plasma nanoparticles more efficient and improving the overall performance of the system. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 and Figure 2 This is a reaction pathway diagram for coupling quantum dots and plasma nanoparticles in a preferred embodiment of the present invention.

[0029] Figure 3 This is a transmission image of the bonding between quantum dots and gold nanoparticles obtained in Example 1 of the present invention.

[0030] Figure 4 This is the scattering absorption spectrum of the device obtained in Example 1 of the present invention.

[0031] Figure 5 This is a transmission image of the bonding between quantum dots and gold nanoparticles obtained in Example 2 of the present invention. DETAILED DESCRIPTION

[0032] The present invention provides a method for coupling quantum dots and plasmonic nanoparticles and a strong coupling device. To clarify the objectives, technical solutions, and effects of the present invention, the present invention is described in further detail below. It should be understood that the specific embodiments described herein are intended only to illustrate the present invention and are not intended to limit the present invention.

[0033] An embodiment of the present invention provides a method for coupling quantum dots and plasma nanoparticles. The method connects quantum dots and plasma nanoparticles through amide bonds to construct a composite system capable of achieving strong coupling.

[0034] The existing chemical bond connecting quantum dots and plasma nanoparticles is a disulfide bond. Specifically, the disulfide bond method is divided into three parts: ① Amino-functionalized plasma nanoparticles: Hexadecyltrimethylammonium bromide (CTAB) molecules are adsorbed on the surface of plasma nanoparticles, and 11-amino-1-undecanethiol hydrochloride (AUT) molecules are used, which have a thiol group at one end and an amino group at the other end. The thiol group is used to couple the AUT molecules to the surface of the plasma nanoparticles, replacing the CTAB molecules and realizing the amino functionalization of the plasma nanoparticles. ② Activated quantum dots: The quantum dots themselves carry mercaptoethylamine ligands, and Traut's reagent is used to convert the primary amine groups on the quantum dot ligands into thiol groups. ③ Disulfide bond coupling: The activated quantum dot solution is mixed with the amino-functionalized plasma nanoparticles, and the thiol groups on the AUT molecules undergo a disulfide bond coupling reaction with the thiol groups on the quantum dot ligands.

[0035] In this embodiment, the quantum dots and plasma nanoparticles are connected by amide bonds. The product obtained by the method of this embodiment will have better stability because the bond energy of the disulfide bond is lower than that of the amide bond, and the amide bond has a stronger bonding force.

[0036] In some embodiments, the method connects quantum dots to plasmonic nanoparticles via amide bonds, and the specific method steps are:

[0037] Method 1, its reaction route is shown in Figure 1 :

[0038] mixing the plasma nanoparticle solution with a solution containing an amino-functionalized compound to react and obtain amino-functionalized plasma nanoparticles;

[0039] Providing a quantum dot solution, wherein the quantum dots have carboxyl groups connected to their surfaces, mixing the quantum dot solution with a cross-linking agent, and activating the carboxyl groups to obtain an activated quantum dot solution;

[0040] mixing the amino-functionalized plasma nanoparticles with the activated quantum dot solution to generate an amide reaction, so that the quantum dots and the plasma nanoparticles are connected by an amide bond, thereby completing the coupling of the quantum dots and the plasma nanoparticles;

[0041] Method 2, its reaction route is shown in Figure 2 :

[0042] mixing the plasma nanoparticle solution with a solution containing a carboxyl functionalized compound to perform carboxyl functionalization, so that the surface of the plasma nanoparticles is modified with carboxyl groups, thereby obtaining carboxyl functionalized plasma nanoparticles;

[0043] mixing the carboxyl functionalized plasma nanoparticles with a crosslinking agent to activate the carboxyl groups to obtain activated plasma nanoparticles;

[0044] Providing a quantum dot solution, wherein the quantum dots have amino groups attached to their surfaces;

[0045] The activated plasma nanoparticles are mixed with the quantum dot solution to generate an amide reaction, so that the quantum dots and the plasma nanoparticles are connected by an amide bond, thereby completing the coupling of the quantum dots and the plasma nanoparticles.

[0046] In some embodiments, the amino-functionalized compound is selected from amino-polyethylene glycol-thiol, the carboxyl-functionalized compound is selected from carboxyl-polyethylene glycol-thiol, and the plasma nanoparticles include plasma gold, silver, etc., wherein the plasma gold further includes gold nanobipyramids, gold nanotriangles, gold nanorods, etc.

[0047] This embodiment uses amino-polyethylene glycol-thiol, carboxyl-polyethylene glycol-thiol and gold nanoparticles as examples: amino-polyethylene glycol-thiol and carboxyl-polyethylene glycol-thiol have high chemical activity, which can improve the conversion rate of the generated product. In addition, after amino-polyethylene glycol-thiol and carboxyl-polyethylene glycol-thiol are connected to the surface of gold nanoparticles, they can reduce particle aggregation and ensure the progress of subsequent reactions.

[0048] In some embodiments, the surface of the plasmonic nanoparticles is modified with hexadecyltrimethylammonium bromide.

[0049] Cetyltrimethylammonium bromide (CTAB) is a stabilizer that is attached to the plasma nanoparticles through electrostatic force, which can stabilize the dispersion of the plasma nanoparticles.

[0050] In some embodiments, in the method, the concentration of the plasma nanoparticle solution is 0.005-0.02 mg / mL, and the concentration of the solution containing the amino-functionalized compound is 2-8x10 -4 mol / L, the dosage ratio of the plasma nanoparticle solution to the solution containing the amino-functionalized compound is 1:(5-50); in the second method, the concentration of the plasma nanoparticle solution is 0.005-0.02 mg / mL, and the concentration of the solution containing the carboxyl-functionalized compound is 2-8x10 -4 mol / L, and the dosage ratio of the plasma nanoparticle solution to the solution containing the carboxyl functionalized compound is 1:(5-50).

[0051] In some embodiments, in the method one, before the step of mixing the amino-functionalized plasma nanoparticles with the activated quantum dot solution, the method further includes the steps of: allowing the mixed solution obtained by reacting the plasma nanoparticle solution with the solution containing the amino-functionalized compound to stand and centrifuge in sequence, and then adding the obtained precipitate to N,N-dimethylformamide to obtain amino-functionalized plasma nanoparticles; in the method two, after the step of mixing the plasma nanoparticle solution with the solution containing the carboxyl-functionalized compound and performing carboxyl functionalization, the method further includes the steps of: allowing the carboxyl-functionalized plasma nanoparticle solution to stand and centrifuge in sequence, and then adding the obtained precipitate to N,N-dimethylformamide to obtain carboxyl-functionalized plasma nanoparticles.

[0052] The subsequent amide reaction will be affected by water, so this example uses N,N-dimethylformamide as a solvent to improve the subsequent reaction conversion rate.

[0053] In some embodiments, in the method 1, the cross-linking agent includes 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysulfosuccinimide sodium salt.

[0054] In some embodiments, in the method 1, the step of mixing the quantum dot solution with the crosslinker is specifically: first adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to the quantum dot solution, and then adding N-hydroxysulfosuccinimide sodium salt.

[0055] 1-Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, as a carboxyl activator, first reacts with the carboxyl group (-COOH) on the quantum dots to generate a highly reactive O-acylisourea intermediate. However, this intermediate is easily hydrolyzed in aqueous solution, resulting in reduced efficiency. This example continues by adding sodium N-hydroxysulfosuccinimide (Sulfo-NHS) to the quantum dot solution. In the presence of Sulfo-NHS, EDC converts the carboxyl group into an amino-reactive Sulfo-NHS ester, which is more stable than the O-acylisourea intermediate.

[0056] In some embodiments, in the second method, the carboxyl-functionalized plasma nanoparticles are subjected to a carboxyl activation treatment, specifically comprising the following steps: first adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to the carboxyl-functionalized plasma nanoparticles, and then adding N-hydroxysulfosuccinimide sodium salt.

[0057] An embodiment of the present invention provides a quantum dot and plasma nanoparticle strong coupling device, which is obtained by coupling using the above method.

[0058] The principle of the device provided in this embodiment is essentially plasmon-exciton resonance, which is manifested here as consisting of a plasma nanoparticle and a quantum dot. Specifically, the process of plasmon-exciton resonance formation is as follows: 1. Excitation: The incident light excites the free electrons in the plasma metal nanoparticles, and the free electrons undergo collective oscillation under the action of the optical field, forming plasmons. 2. Coupling: Plasmons interact with nearby excitons (provided by quantum dots). 3. Mixed state formation: The energy exchange between plasmons and excitons forms a new mixed state (polaritons), which has the dual characteristics of plasmons and excitons. 4. Spectral manifestation: Rabi splitting is observed in the scattering spectrum, that is, two new resonance peaks, corresponding to the upper mixed state and the lower mixed state, respectively.

[0059] The following is a clear and complete description of the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only some of the embodiments of the present invention, not all of them, and are intended only to illustrate the present invention and in no way limit the present invention. All other embodiments derived by persons of ordinary skill in the art based on the embodiments of the present invention without inventive effort are also within the scope of protection of the present invention.

[0060] Example 1

[0061] A method for preparing a quantum dot and plasma nanoparticle strong coupling device comprises the following steps:

[0062] 1 mL of 0.01 mg / mL gold nanoparticle solution (Au bps longitudinal plasmon resonance peak: 785 ± 5 nm) was added with stirring to 4 × 10 -4mol / L 20uL amino-polyethylene glycol-thiol solution, the stirring speed is 800r / min, the stirring time is 2h, and after the stirring is completed, it is allowed to stand for 24 hours, and then centrifuged at 7000r / min for 10 minutes, allowed to stand, the lower layer of precipitate is removed, 1mL N,N-dimethylformamide is added to the lower layer of precipitate, and placed in an ultrasonic machine and maintained below 35°C for 5 minutes to obtain amino-functionalized plasma gold nanoparticles; 0.25mg / mL50 uL quantum dots connected with carboxyl groups (CdTe core-type quantum dots (COOH functionalized, fluorescenceλem 770nm, powder) from sigma) solution are added with stirring in sequence 6.4mg / mL 10uL 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 6.4mg / mL 10uL N-hydroxysulfosuccinimide sodium salt was stirred for 2 hours to complete the carboxyl activation. Then, 10 μL of carboxyl-activated quantum dot solution was added to the amino-functionalized plasma gold nanoparticles obtained above. The reaction was allowed to stand for a period of time to allow the plasma gold nanoparticles and quantum dots to bond. The bonding transmission diagram is shown in FIG. Figure 3 As shown, a quantum dot and plasma nanoparticle strong coupling device is obtained, and its scattering absorption spectrum is shown in Figure 4 shown.

[0063] Example 2

[0064] A method for preparing a quantum dot and plasma nanoparticle coupling device comprises the following steps:

[0065] Take 1 mL of 0.01 mg / mL gold nanoparticle solution (Au bps longitudinal plasmon resonance peak: 785 ± 5 nm) and add 20 μL of 4 × 10 -4 mol / L carboxyl-polyethylene glycol-thiol solution, the stirring speed is 800r / min, the stirring time is 2 hours, and after the stirring is completed, it is allowed to stand for 24 hours, and then centrifuged at 7000r / min for 10 minutes, the lower layer of precipitate is removed, and 1mL N,N-dimethylformamide solution is added to the lower layer of precipitate. To the solution to which N,N-dimethylformamide has been added, 10uL 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride solution and 10uL N-hydroxysulfosuccinimide sodium salt solution are added while stirring. The stirring speed is 800r / min. After stirring for 2 hours, 16uL of 0.1nmol / mLQD solution ((625nm)CdSe / ZnS-PEG-NH2 type: CdSe / ZnS QDs from Suzhou Xingshuo Nanotechnology Co., Ltd.) is added to the above mixed solution to bond the plasmonic gold nanoparticles and quantum dots. The bonding transmission graph is shown in FIG. Figure 5As shown, the quantum dot and plasma nanoparticle coupling device is obtained.

[0066] It should be understood that the application of the present invention is not limited to the above examples. For those skilled in the art, improvements or changes can be made based on the above description. All these improvements and changes should fall within the scope of protection of the claims attached to the present invention.

Claims

1. A method for coupling quantum dots and plasma nanoparticles, characterized in that: The method connects quantum dots and plasma nanoparticles via amide bonds to construct a composite system capable of achieving strong coupling.

2. The method for coupling quantum dots and plasma nanoparticles according to claim 1, wherein: The method connects quantum dots to plasmonic nanoparticles via amide bonds, and the specific steps are as follows: Method 1: mixing the plasma nanoparticle solution with a solution containing an amino-functionalized compound to react and obtain amino-functionalized plasma nanoparticles; Providing a quantum dot solution, wherein the quantum dots have carboxyl groups connected to their surfaces, mixing the quantum dot solution with a cross-linking agent, and activating the carboxyl groups to obtain an activated quantum dot solution; mixing the amino-functionalized plasma nanoparticles with the activated quantum dot solution to generate an amide reaction, so that the quantum dots and the plasma nanoparticles are connected by an amide bond, thereby completing the coupling of the quantum dots and the plasma nanoparticles; Method 2: mixing the plasma nanoparticle solution with a solution containing a carboxyl functionalized compound to perform carboxyl functionalization, so that the surface of the plasma nanoparticles is modified with carboxyl groups, thereby obtaining carboxyl functionalized plasma nanoparticles; mixing the carboxyl functionalized plasma nanoparticles with a crosslinking agent to activate the carboxyl groups to obtain activated plasma nanoparticles; Providing a quantum dot solution, wherein the quantum dots have amino groups attached to their surfaces; The activated plasma nanoparticles are mixed with the quantum dot solution to generate an amide reaction, so that the quantum dots and the plasma nanoparticles are connected by an amide bond, thereby completing the coupling of the quantum dots and the plasma nanoparticles.

3. The method for coupling quantum dots and plasma nanoparticles according to claim 2, wherein: The amino-functionalized compound is selected from amino-polyethylene glycol-thiol, and the carboxyl-functionalized compound is selected from carboxyl-polyethylene glycol-thiol.

4. The method for coupling quantum dots and plasma nanoparticles according to claim 2, wherein: The surface of the plasma nanoparticles is modified by hexadecyltrimethylammonium bromide.

5. The method for coupling quantum dots and plasma nanoparticles according to claim 2, wherein: In the method 1, the concentration of the plasma nanoparticle solution is 0.005-0.02 mg / mL, and the concentration of the solution containing the amino-functionalized compound is 2-8x10 -4 mol / L, the dosage ratio of the plasma nanoparticle solution to the solution containing the amino-functionalized compound is 1:(5-50); in the second method, the concentration of the plasma nanoparticle solution is 0.005-0.02 mg / mL, and the concentration of the solution containing the carboxyl-functionalized compound is 2-8x10 -4 mol / L, and the dosage ratio of the plasma nanoparticle solution to the solution containing the carboxyl functionalized compound is 1:(5-50).

6. The method for coupling quantum dots and plasma nanoparticles according to claim 2, wherein: In the first method, before the step of mixing the amino-functionalized plasma nanoparticles with the activated quantum dot solution, the method further comprises the steps of: allowing the plasma nanoparticle solution to react with the solution containing the amino-functionalized compound to stand and centrifuge the resulting mixed solution, and then adding the resulting precipitate to N,N-dimethylformamide to obtain amino-functionalized plasma nanoparticles; In the second method, after the step of mixing the plasma nanoparticle solution with a solution containing a carboxyl-functionalized compound and performing the carboxyl-functionalization step, the method further includes the steps of: allowing the carboxyl-functionalized plasma nanoparticle solution to stand and centrifuge in sequence, and then adding the obtained precipitate to N,N-dimethylformamide to obtain carboxyl-functionalized plasma nanoparticles.

7. The method for coupling quantum dots and plasma nanoparticles according to claim 2, wherein: In the method 1, the cross-linking agent includes 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysulfosuccinimide sodium salt.

8. The method for coupling quantum dots and plasma nanoparticles according to claim 6, wherein: In the method 1, the step of mixing the quantum dot solution with the crosslinking agent is specifically as follows: firstly adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to the quantum dot solution, and then adding N-hydroxysulfosuccinimide sodium salt.

9. The method for coupling quantum dots and plasma nanoparticles according to claim 2, wherein: In the second method, the carboxyl-functionalized plasma nanoparticles are subjected to a carboxyl activation treatment, specifically comprising the following steps: first, adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride to the carboxyl-functionalized plasma nanoparticles, and then adding N-hydroxysulfosuccinimide sodium salt.

10. A quantum dot and plasma nanoparticle strong coupling device, characterized in that: The quantum dot and plasma nanoparticle strong coupling device is obtained by coupling using the method described in any one of claims 1 to 9.

Images